FDA Advisers Back Moderna's Covid-19 Vaccine

The transcript discusses the FDA's emergency clearance process for COVID-19 vaccines, focusing on Pfizer and Moderna. It covers vaccine distribution, production challenges, and allocation issues faced by states. The importance of building public confidence in vaccine safety and addressing concerns about long-term effects is emphasized. The FDA's thorough review process and the rarity of severe allergic reactions are highlighted to reassure the public.

What is the expected timeline for the FDA to grant emergency clearance for the Moderna vaccine?

What issues have some state governors reported regarding vaccine allocation?

What concerns do some medical professionals have regarding the COVID-19 vaccine?

How did the FDA ensure public confidence in the vaccine approval process?

What was the efficacy rate reported for the Pfizer and Moderna vaccines?